Is Amarin Sitting on a Goldmine?

Stocks that skyrocket by nearly 500% in less than 12 months aren't normally bargains. Far from it. But the mid-cap biopharma Amarin (NASDAQ: AMRN) could be one of the few exceptions to this general rule of thumb.